Enzalutamide for patients with metastatic castration-resistant prostate cancer
Objective To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI®) in metastatic castration-resistant prostate cancer. Data sources Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and cas...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | article |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/10725/6824 http://dx.doi.org/10.2147/OTT.S80488 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|